Intravenous Edaravone plus Therapeutic Hypothermia Offers Limited Neuroprotection in the Hypoxic-Ischaemic Newborn Piglet

被引:4
|
作者
Yamato, Satoshi Hamano [1 ]
Nakamura, Shinji [1 ]
Htun, Yinmon [1 ]
Nakamura, Makoto [2 ]
Jinnai, Wataru [3 ]
Nakao, Yasuhiro [1 ]
Mitsuie, Tsutomu [1 ]
Koyano, Kosuke [3 ]
Wakabayashi, Takayuki [1 ]
Morimoto, Aya Hashimoto [1 ]
Sugino, Masashiro [4 ]
Iwase, Takashi [1 ]
Kondo, Sonoko Ijichi [1 ]
Yasuda, Saneyuki [1 ]
Ueno, Masaki [5 ]
Miki, Takanori [6 ]
Kusaka, Takashi [1 ]
机构
[1] Kagawa Univ, Fac Med, Dept Pediat, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan
[2] Natl Hosp Org Okayama Med Ctr, Dept Neonatol, Okayam, Japan
[3] Kagawa Univ, Fac Med, Maternal Perinatal Ctr, Miki, Kagawa, Japan
[4] Shikoku Med Ctr Children & Adults, Div Neonatol, Zentsuji, Kagawa, Japan
[5] Kagawa Univ, Fac Med, Dept Pathol & Host Def, Miki, Kagawa, Japan
[6] Kagawa Univ, Fac Med, Dept Anat & Neurobiol, Miki, Kagawa, Japan
基金
日本学术振兴会;
关键词
Edaravone; Hypoxic-ischemic encephalopathy; Piglet; Therapeutic hypothermia; FREE-RADICAL SCAVENGER; TRANSIENT FOCAL ISCHEMIA; CEREBRAL BLOOD-VOLUME; INFLAMMATORY RESPONSES; BRAIN-INJURY; MODEL; MCI-186; ENCEPHALOPATHY; PEROXIDATION; METABOLISM;
D O I
10.1159/000511085
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Therapeutic hypothermia (TH) is a standard therapy for neonatal hypoxic-ischaemic encephalopathy. One potential additional therapy is the free radical scavenger edaravone (EV; 3-methyl-1-phenyl-2-pyrazolin-5-one). Objectives and Methods: This study aimed to compare the neuroprotective effects of edaravone plus therapeutic hypothermia (TH + EV) with those of TH alone after a hypoxic-ischaemic insult in the newborn piglet. Anaesthetized piglets were subjected to 40 min of hypoxia (3-5% inspired oxygen), and cerebral ischaemia was assessed using cerebral blood volume. Body temperature was maintained at 39.0 +/- 0.5 degrees C in the normothermia group (NT, n = 8) and at 33.5 +/- 0.5 degrees C (24 h after the insult) in the TH (n = 7) and TH + EV (3 mg/kg intravenous every 12 h for 3 days after the insult; n = 6) groups under mechanical ventilation. Results: Five days after the insult, the mean (standard deviation) neurological scores were 10.9 (5.7) in the NT group, 17.0 (0.4) in the TH group (p = 0.025 vs. NT), and 15.0 (3.9) in the TH + EV group. The histopathological score of the TH + EV group showed no significant improvement compared with that of the other groups. Conclusion: TH + EV had no additive neuroprotective effects after hypoxia-ischaemia in neurological and histopathological assessments.
引用
收藏
页码:713 / 720
页数:8
相关论文
共 50 条
  • [41] Active cooling temperature required to achieve therapeutic hypothermia correlates with short-term outcome in neonatal hypoxic-ischaemic encephalopathy
    Mietzsch, Ulrike
    Radhakrishnan, Rupa
    Boyle, Frances A.
    Juul, Sandra
    Wood, Thomas R.
    JOURNAL OF PHYSIOLOGY-LONDON, 2020, 598 (02): : 415 - 424
  • [42] Embedding the 'CoolCuddle' intervention for infants undergoing therapeutic hypothermia for hypoxic-ischaemic encephalopathy in NICU: an evaluation using normalisation process theory
    Beasant, Lucy
    Chakkarapani, Ela
    Horwood, Jeremy
    Odd, David
    Stocks, Stephanie
    Parker, Denise
    Ingram, Jenny
    BMJ OPEN, 2024, 14 (10):
  • [43] Outcomes of neonatal hypoxic-ischaemic encephalopathy in centres with and without active therapeutic hypothermia: a nationwide propensity score-matched analysis
    Shipley, Lara
    Mistry, Aarti
    Sharkey, Don
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2022, 107 (01): : 6 - 12
  • [44] Hyperglycaemia in infants with hypoxic-ischaemic encephalopathy is associated with improved outcomes after therapeutic hypothermia: a post hoc analysis of the CoolCap Study
    Basu, Sudeepta K.
    Salemi, Jason L.
    Gunn, Alistair J.
    Kaiser, Jeffrey R.
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2017, 102 (04): : F299 - F306
  • [45] Therapeutic hypothermia for neonates with hypoxic-ischaemic encephalopathy in low- and lower-middle-income countries: a systematic review and meta-analysis
    Prakash, Raj
    Reyes-Garcia, Diana Veronica
    Hansoge, Sanjana Somanath
    Rosenkrantz, Ted S.
    JOURNAL OF TROPICAL PEDIATRICS, 2024, 70 (05)
  • [46] Neurodevelopmental outcome in neonates with hypoxic-ischaemic encephalopathy managed with therapeutic hypothermia in a tertiary-level public hospital outside an intensive care unit setting
    Mbatha, S.
    Nakwa, F. L.
    Thandrayen, K.
    Velaphi, S.
    PAEDIATRICS AND INTERNATIONAL CHILD HEALTH, 2021, 41 (03) : 171 - 176
  • [47] Therapeutic Hypothermia Using Gel Packs for Term Neonates with Hypoxic Ischaemic Encephalopathy in Resource-limited Settings: a Randomized Controlled Trial
    Bharadwaj, Shruthi K.
    Bhat, B. Vishnu
    JOURNAL OF TROPICAL PEDIATRICS, 2012, 58 (05) : 382 - 388
  • [48] Role of EEG background activity, seizure burden and MRI in predicting neurodevelopmental outcome in full-term infants with hypoxic-ischaemic encephalopathy in the era of therapeutic hypothermia
    Weeke, Lauren C.
    Boylan, Geraldine B.
    Pressler, Ronit M.
    Hallberg, Boubou
    Blennow, Mats
    Toet, Mona C.
    Groenendaal, Floris
    de Vries, Linda S.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2016, 20 (06) : 855 - 864
  • [49] Therapeutic hypothermia initiated within 6 hours of birth is associated with reduced brain injury on MR biomarkers in mild hypoxic-ischaemic encephalopathy: a non-randomised cohort study
    Montaldo, Paolo
    Lally, Peter J.
    Oliveira, Vania
    Swamy, Ravi
    Mendoza, Josephine
    Atreja, Gaurav
    Kariholu, Ujwal
    Shivamurthappa, Vijayakumar
    Liow, Natasha
    Teiserskas, Justinas
    Pryce, Russell
    Soe, Aung
    Shankaran, Seetha
    Thayyil, Sudhin
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2019, 104 (05): : F515 - F520
  • [50] Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial
    Matsuyama, Nao
    Shimizu, Shinobu
    Ueda, Kazuto
    Suzuki, Toshihiko
    Suzuki, Sakiko
    Miura, Ryosuke
    Katayama, Akemi
    Ando, Masahiko
    Mizuno, Masaaki
    Hirakawa, Akihiro
    Hayakawa, Masahiro
    Sato, Yoshiaki
    BMJ OPEN, 2022, 12 (04):